Seattle, Washington-- Putting its $2 million Series A round on hold, PharmaIN Ltd. has received $3 million grant from the National Institutes of Health grant for its Type 1 diabetes product. But to finance the same drug for Type 2 diabetes, the company said it will now seek up to $10 million in funding.
